Bioventus will announce Q2 2025 financial results on August 6, 2025, followed by a conference call for updates.
Quiver AI Summary
Bioventus Inc. announced that it will release its financial results for the second quarter of fiscal year 2025 on August 6, 2025, before the market opens. The company will hold a conference call at 8:30 a.m. Eastern Time on the same day to discuss these results and offer a business update. Participants can join the call by dialing 1-800-715-9871 or by accessing a live webcast available on the Company's Investor Relations website, which will also archive the presentation for replay until August 5, 2026. Bioventus focuses on providing innovative, clinically proven products aimed at facilitating active healing, with a commitment to quality and ethical practices.
Potential Positives
- Bioventus is set to report its second-quarter financial results, indicating ongoing transparency and communication with investors.
- The scheduled conference call showcases the company's commitment to providing updates on business performance and future direction.
- The press release highlights Bioventus's dedication to innovations in active healing, positioning the company as a leader in the healthcare sector.
Potential Negatives
- Absence of financial results in the press release may raise concerns about the company's transparency or performance in the second quarter of fiscal year 2025.
FAQ
When will Bioventus report its Q2 2025 financial results?
Bioventus will report its Q2 2025 financial results on August 6, 2025, before the market opens.
What time is the Bioventus conference call?
The conference call will take place at 8:30 a.m. Eastern Time on August 6, 2025.
How can I participate in the Bioventus conference call?
To participate, dial 1-800-715-9871 and refer to the Bioventus Conference Call or use conference ID 1859022.
Where can I find the webcast of the conference call?
The webcast will be available in the “Investor Relations” section of Bioventus's website at https://ir.bioventus.com/.
How long will the webcast replay be available?
The webcast replay will be available until August 5, 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BVS Insider Trading Activity
$BVS insiders have traded $BVS stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $BVS stock by insiders over the last 6 months:
- MARK LEONARD SINGLETON (SVP & CFO) has made 0 purchases and 3 sales selling 15,852 shares for an estimated $149,187.
- ANTHONY D'ADAMIO (SVP & General Counsel) has made 0 purchases and 3 sales selling 9,953 shares for an estimated $92,520.
- KATRINA J CHURCH (SVP & Chief Compliance Officer) has made 0 purchases and 3 sales selling 3,838 shares for an estimated $35,299.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BVS Hedge Fund Activity
We have seen 70 institutional investors add shares of $BVS stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DIVISADERO STREET CAPITAL MANAGEMENT, LP added 1,692,149 shares (+inf%) to their portfolio in Q1 2025, for an estimated $15,483,163
- OPHIR ASSET MANAGEMENT PTY LTD removed 424,708 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,886,078
- DRIEHAUS CAPITAL MANAGEMENT LLC added 325,402 shares (+29.1%) to their portfolio in Q1 2025, for an estimated $2,977,428
- SEGALL BRYANT & HAMILL, LLC removed 303,082 shares (-85.9%) from their portfolio in Q1 2025, for an estimated $2,773,200
- KNIGHTS OF COLUMBUS ASSET ADVISORS LLC added 290,700 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,924,434
- INVESCO LTD. added 248,932 shares (+1303.6%) to their portfolio in Q1 2025, for an estimated $2,277,727
- RENAISSANCE TECHNOLOGIES LLC added 164,800 shares (+42.4%) to their portfolio in Q1 2025, for an estimated $1,507,920
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BVS Analyst Ratings
Wall Street analysts have issued reports on $BVS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 03/17/2025
To track analyst ratings and price targets for $BVS, check out Quiver Quantitative's $BVS forecast page.
$BVS Price Targets
Multiple analysts have issued price targets for $BVS recently. We have seen 2 analysts offer price targets for $BVS in the last 6 months, with a median target of $13.5.
Here are some recent targets:
- Ross Osborn from Cantor Fitzgerald set a target price of $12.0 on 07/07/2025
- Caitlin Cronin from Canaccord Genuity set a target price of $15.0 on 03/17/2025
Full Release
DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”) , a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market opens on Wednesday, August 6, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.
To participate in the conference call, dial 1-800-715-9871 and refer either to the Bioventus Inc. Conference Call or the conference ID 1859022.
A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company's website at https://ir.bioventus.com/ . The webcast will be archived at the same site and available for replay until August 5, 2026.
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit
www.bioventus.com
and follow the Company on
LinkedIn
and
Twitter
. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Investor and Media Inquiries:
Dave Crawford
919-474-6787
[email protected]
